<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Signaling of the thrombopoietin (THPO) receptor MPL is critical for the maintenance of hematopoietic stem cells (<z:chebi fb="15" ids="50443">HSCs</z:chebi>) and megakaryocytic differentiation </plain></SENT>
<SENT sid="1" pm="."><plain>Inherited loss-of-function mutations of MPL cause severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, a syndrome called congenital <z:hpo ids='HP_0004859'>amegakaryocytic thrombocytopenia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CAMT</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>With the aim to assess the toxicity of retroviral expression of Mpl as a basis for further development of a gene therapy for this disorder, we expressed Mpl in a murine bone marrow transplantation (BMT) model </plain></SENT>
<SENT sid="3" pm="."><plain>Treated mice developed a profound yet transient elevation of multilineage hematopoiesis, which showed morphologic features of a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>) with progressive <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Ten percent of mice (3/27) developed <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e>, associated with insertional activation of Sfpi1 and Fli1 </plain></SENT>
<SENT sid="5" pm="."><plain>The majority of transplanted mice developed a progressive <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> with histopathological features of a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)-like disorder </plain></SENT>
<SENT sid="6" pm="."><plain>To avoid these adverse reactions, improved retroviral vectors were designed that mediate reduced and more physiological Mpl expression </plain></SENT>
<SENT sid="7" pm="."><plain>Self-inactivating gamma-retroviral vectors were constructed that expressed Mpl from the phosphoglycerate kinase (PGK) or the murine Mpl promoter </plain></SENT>
<SENT sid="8" pm="."><plain>Mice that received BM cells expressing Mpl from the Mpl promoter were free of any previously observed adverse reactions </plain></SENT>
</text></document>